VECT News and Press, VectivBio Holding AG From 03/29/22

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies -- BASEL, Switzerland, M...

-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD) -- -- Data support regenerative, non-immunosuppressive hypothesis f...

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Found...

Gainers: Arhaus (NASDAQ:ARHS) +6%. Radware (NASDAQ:RDWR) +5%. Liquidity Services (NASDAQ:LQDT) +5%. Digital World Acquisition (NASDAQ:DWAC) +3%. Big 5 Sporting Goods (NASDAQ:BGFV) +26%. Losers: Lucid Group (NASDAQ:LCID) -8%. Relmada Therapeutics (NASDAQ:RLMD) -7%. VectivBio Holding AG (NASDAQ...

Trading in VectivBio Holding (VECT +16.4%) has been on a roller-coaster ride today, as shares were down this morning but making a strong recovery in the afternoon. As of 313p ET, 499K shares had traded hands. That's more than 10 times the average daily volume of 44,755 shares. The volatility ...

-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with the Acquisition of CoMET Small Molecule Platform for Inherited Metabolic Diseases (I...

BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Found...

-FDA clears IND Application for Apraglutide for Acute Graft-Versus-Host Disease - Dosing of first patient expected in 1Q 2022 - - Interim data anticipated in 2H 2022 - - FDA previously granted orphan drug designation for apraglutide for the prevention of acute gr...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced...